PRESS RELEASE
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Agricultural biotech companies are constantly working on ways to up- or down regulate gene expression to influence traits of crops. Annogen’s services and technology contribute to these efforts by identifying the non-coding elements in the genome that underlie gene expression and repression as well as by performing mutagenesis screens on these elements to analyze the impact of non-coding mutations on gene expression.
While Annogen has its primary focus on medical applications like cell therapy and drug discovery, it has also already established the applicability of its SuRE™ technology in animals and plants. Joris van Arensbergen, founder and CEO, is pleased with another collaboration in this field: “This projects fits in a trends we are now seeing where people want to apply SuRE™ both to validate AI predictions as well as to provide datasets for AI training purposes. We are very excited to be part of these developments”.
About Annogen
At Annogen we use our SuRE technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression and we establish databases in which we functionally annotate millions of non-coding sequence variants for their effect on promoter and enhancer activity. This enables researchers to qualitatively interpret non-coding sequence variants in humans, animals and plants in the way we already can for coding sequence variants. For more information, please visit www.annogen.bio.
For further information
Victor Schut, CBO at Annogen, victor@annogen.bio
